LigaChem Biosciences Past Earnings Performance
Past criteria checks 0/6
LigaChem Biosciences's earnings have been declining at an average annual rate of -32.4%, while the Life Sciences industry saw earnings growing at 22.4% annually. Revenues have been declining at an average rate of 0.1% per year.
Key information
-32.4%
Earnings growth rate
-27.3%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | -0.1% |
| Return on equity | -7.4% |
| Net Margin | -80.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23
A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07
Revenue & Expenses Breakdown
How LigaChem Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 57,543 | -46,543 | 20,112 | 79,586 |
| 31 Dec 23 | 34,146 | -73,704 | 17,248 | 79,609 |
| 30 Sep 23 | 34,470 | -83,053 | 25,676 | 71,490 |
| 30 Jun 23 | 35,643 | -71,784 | 16,316 | 71,490 |
| 31 Mar 23 | 35,266 | -54,336 | 17,247 | 59,986 |
| 31 Dec 22 | 33,412 | -45,092 | 15,437 | 51,110 |
| 30 Sep 22 | 41,783 | -5,173 | 5,624 | 33,942 |
| 30 Jun 22 | 39,789 | -5,443 | -5,971 | 43,719 |
| 31 Dec 21 | 32,157 | -23,391 | 4,707 | 39,071 |
| 31 Dec 19 | 57,500 | 13,586 | 7,977 | 16,711 |
| 30 Sep 19 | 51,280 | -1,073 | 5,518 | 14,290 |
| 30 Jun 19 | 29,947 | -24,220 | 5,037 | 16,807 |
| 31 Mar 19 | 28,452 | -23,197 | 4,957 | 15,533 |
| 31 Dec 18 | 25,240 | -25,770 | 4,856 | 15,505 |
| 30 Sep 18 | 24,869 | -15,221 | 5,756 | 13,629 |
| 30 Jun 18 | 23,907 | -10,598 | 5,658 | 8,894 |
| 31 Mar 18 | 23,177 | -12,034 | 7,701 | 6,907 |
| 31 Dec 17 | 22,057 | -12,934 | 5,815 | 9,263 |
| 30 Sep 17 | 20,790 | -15,746 | 5,288 | 9,072 |
| 30 Jun 17 | 18,845 | -15,890 | 5,163 | 8,841 |
| 31 Mar 17 | 17,541 | -16,183 | 3,370 | 11,355 |
| 31 Dec 16 | 16,655 | -14,725 | 5,022 | 7,813 |
| 30 Sep 16 | 13,720 | -8,330 | 4,561 | 7,576 |
| 30 Jun 16 | 10,294 | -8,192 | 3,427 | 7,310 |
| 31 Mar 16 | 6,295 | -7,671 | 2,332 | 6,680 |
| 31 Dec 15 | 1,788 | -8,237 | 2,094 | 7,000 |
| 31 Dec 14 | 870 | -8,686 | 1,605 | 7,679 |
Quality Earnings: A141080 is currently unprofitable.
Growing Profit Margin: A141080 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A141080 is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare A141080's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A141080 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.9%).
Return on Equity
High ROE: A141080 has a negative Return on Equity (-7.41%), as it is currently unprofitable.